Fundraising Overview - The company raised a total of RMB 1,985,400,000.00 from its initial public offering, with a net amount of RMB 1,800,516,648.50 after deducting issuance costs [1][2] - As of June 30, 2025, the remaining balance of the raised funds is RMB 407,598,543.69, which includes RMB 10,379,460.36 in special accounts and RMB 397,219,083.33 in cash management [1][2] Fund Utilization - The company has utilized RMB 1,368,308,738.68 from the raised funds in previous years and RMB 100,060,957.44 in the current period for investment projects [1][2] - The total surplus funds, including interest income, amount to RMB 98,901,084.25, with RMB 7,682,000.92 in special accounts and RMB 91,219,083.33 in cash management [2][6] Fund Management - The company has established a special account management system for the raised funds, ensuring compliance with relevant laws and regulations [1][2] - The company has signed tripartite or quadripartite supervision agreements with various banks and the sponsoring institution to ensure proper management of the funds [1][2] Project Status - The projects funded by the raised capital, including the "PCBA Production Workshop Intelligent Transformation Project," "Intelligent Video Product Production Line Construction Project," and "Intelligent Audio Product Production Line Construction Project," have been completed [6][7] - The company has not experienced any changes in the implementation locations or methods for the fundraising projects during the reporting period [2][6] Surplus and Unused Funds - The company has not used idle funds to temporarily supplement working capital during the reporting period [2][6] - As of June 30, 2025, the company has an unused balance of RMB 407,598,543.69 in raised funds, which will be allocated for future project payments and cash management activities [2][6] Compliance and Verification - The sponsoring institution has verified that the company's management and use of the raised funds comply with relevant regulations, and there are no violations in the use of the funds [2][6] - The company has adhered to necessary review procedures when using the raised funds, ensuring that there are no changes in the intended use that could harm shareholder interests [2][6]

Group 1 - The fourth meeting of the board of directors of Zhangjiagang Haiguo New Energy Equipment Co., Ltd. was held on August 27, 2025, with all seven directors present, confirming the legality and validity of the meeting [1] - The board approved the 2025 semi-annual report and its summary, which accurately reflects the company's operational and financial status during the reporting period [1][2] - The board confirmed that the use of raised funds complied with relevant regulations and there were no violations or changes that could harm shareholder interests [2][3] Group 2 - The board approved the provision for credit impairment losses and asset impairment losses, aligning with accounting standards and reflecting the company's actual situation [2][3] - The company plans to revise its articles of association and seek shareholder approval for related business registration changes [3] - The board agreed to enhance governance structures and operational standards in accordance with relevant laws and regulations [3][6] Group 3 - The board appointed Ms. Yu Danyang as the securities affairs representative to assist the board secretary [6] - A temporary shareholders' meeting is scheduled for September 12, 2025 [6] - All resolutions passed during the meeting received unanimous approval from the directors [4][5]

Group 1 - The board of directors of Shenchi Electromechanical Co., Ltd. held its sixth meeting of the fifth session, with all nine directors present, and the meeting complied with relevant laws and regulations [1] - The board approved the proposal for the 2025 semi-annual report and its summary, with a unanimous vote of 9 in favor [1] - The board also approved the special report on the storage and use of raised funds for the first half of 2025, with a unanimous vote of 9 in favor [2] Group 2 - The board approved the proposal to increase the expected amount of daily related transactions for 2025, with 8 votes in favor and 1 abstention [2] - The board approved the use of idle raised funds for cash management, allowing up to 200 million RMB to be used within 12 months, with a unanimous vote of 9 in favor [3] - The board approved the establishment of a securities investment management system to regulate investment behavior and protect investor interests, with a unanimous vote of 9 in favor [3] Group 3 - The board approved the revision of the internal audit system to strengthen internal control management and promote healthy development, with a unanimous vote of 9 in favor [4]

Core Viewpoint - Qingdao Weilan Biological Co., Ltd. has provided a detailed report on the management and usage of raised funds for the first half of 2025, ensuring compliance with regulatory requirements and transparency in financial practices [1]. Fundraising Overview - The company raised a total of RMB 394 million through its initial public offering (IPO), with a net amount of RMB 347 million after deducting issuance costs [1]. - The non-public offering raised RMB 500 million, with a net amount after costs also verified by an accounting firm [1]. Fund Management - The company has established a dedicated fund management policy to ensure the effective use of raised funds, adhering to relevant laws and regulations [1]. - Funds are stored in special accounts, and the company has signed tripartite supervision agreements with banks to ensure proper management [1][2]. Fund Usage - As of June 30, 2025, the company has utilized RMB 346.34 million from the IPO funds and RMB 498.10 million from the non-public offering funds for various projects [4][5]. - The company has not used any raised funds for temporary working capital or to replace pre-invested funds in the projects [5][6]. Project Changes - The company has made several changes to its fundraising projects, including the implementation subject and location for the "Annual Production of 10,000 Tons of Plant Microecological Preparations" project, which is now managed by a wholly-owned subsidiary [3][12]. - The company has also adjusted the use of unspent funds from previous projects to new project investments, ensuring compliance with regulations [4][6]. Financial Performance - The company reported that the cumulative investment in the "Annual Production of 10,000 Tons of Plant Microecological Preparations" project reached RMB 73.31 million, while the "Animal Health Products Comprehensive Production Base" project was completed with a total investment of RMB 104.16 million [8][10]. - The company has not encountered any significant issues in the usage and disclosure of raised funds, maintaining transparency and compliance with regulatory requirements [7][11].

上海雅仕投资发展股份有限公司 募集资金管理办法 上海雅仕投资发展股份有限公司 募集资金管理办法 二〇二五年八月 上海雅仕投资发展股份有限公司 募集资金管理办法 第一章 总则 第一条 为加强、规范募集资金的管理，提高资金使用效率和效益，根据《公 司法》《证券法》《上海证券交易所股票上市规则》《上市公司募集资金监管规 则》《上海证券交易所上市公司自律监管指引第1号——规范运作》和《上海雅 仕投资发展股份有限公司章程》（以下简称"《公司章程》"）及其他法律法规和 规定，结合公司实际情况，特制定本办法。 第二条 本办法所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金，但不包括公司实施股权激励计划 募集的资金。募集的资金须经具有证券从业资格的会计师事务所审验并出具验资 报告。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能力和创新能力。募集资金不得用于持有财务性投 资，不得直接或者间接投资于以买卖有价证券为主要业务的公司。 第一款所称财务性投资的理解和适 ...

罗博特科智能科技股份有限公司 募集资金管理办法 罗博特科智能科技股份有限公司 募集资金管理办法 第一章 总则 第一条 为规范罗博特科智能科技股份有限公司（以下简称"公司"）募集资 金的管理和使用，保护投资者的权益，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《深圳证券交 易所创业板股票上市规则》 （以下简称"《创业板股票上市规则》"）《深圳证券交易 所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 （以下简称"《创 业板上市公司规范运作》"）《上市公司募集资金监管规则》以及《罗博特科智能科 技股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，制定本办法。 第二条 本办法所称募集资金是指公司通过发行股票或者其他具有股权性质 的证券，向投资者募集并用于特定用途的资金，不包括公司为实施股权激励计划 募集的资金。 第三条 公司募集资金应当专款专用。公司使用募集资金应当符合国家产业 政策和相关法律法规，践行可持续发展理念，履行社会责任，原则上应当用于主 营业务，有利于增强公司竞争能力和创新能力。中国证券监督管理委员会对公司 发行股份、可 ...

Group 1 - The board of directors of Robotech Co., Ltd. held its 31st meeting on August 27, 2025, to review the company's 2025 semi-annual report, which was deemed to accurately reflect the company's operational status without any false records or misleading statements [1][2] - The board unanimously approved the management and use of raised funds in compliance with relevant regulations, confirming no violations or changes that could harm shareholder interests [2][3] - A three-year shareholder return plan (2025-2027) was established to enhance transparency and protect shareholder rights, which will be submitted for approval at the upcoming extraordinary general meeting [3][4] Group 2 - The board nominated candidates for the fourth board of directors, including both non-independent and independent directors, with all candidates receiving unanimous approval from the current board [5][6][8] - The company plans to appoint a new accounting firm, Zhitong CPA, following the expiration of the contract with the previous firm, Tianjian CPA, with both firms having no objections to the change [8][9] - Amendments to the company's governance structure and articles of association were approved to align with legal requirements and improve operational standards, pending further review at the extraordinary general meeting [10][11]

证券代码：300757 证券简称：罗博特科 公告编号：2025-073 罗博特科智能科技股份有限公司（以下简称"公司"）第三届监事会第二十七 次会议于 2025 年 8 月 27 日在苏州工业园区唯亭街道港浪路 3 号罗博特科 A 栋 四楼会议室以通讯表决的方式召开。本次会议通知已于 2025 年 8 月 15 日以电子 邮件形式通知全体监事。本次会议应出席监事 3 人，实际出席监事 3 人。本次会 议由公司监事会主席张学强先生召集并主持，本次会议的召集、召开及表决程序 符合《公司法》及《公司章程》的有关规定，会议决议合法有效。 二、监事会会议审议情况 本次会议以记名方式投票表决，审议通过了以下事项： 经审核，监事会认为：董事会编制和审议的公司《2025 年半年度报告》及 《2025 年半年度报告摘要》的程序符合相关法律法规，报告内容真实、准确、 完整地反映了公司 2025 年上半年度经营的实际情况，不存在虚假记载、误导性 陈述或重大遗漏。 具体内容详见公司同日刊登于巨潮资讯网（http://www.cninfo.com.cn）的 《2025 年半年度报告》和《2025 年半年度报告摘要》。 表决结果：3 票 ...

证券代码：300757 证券简称：罗博特科 公告编号：2025-074 公司依照相关规定对上述募集资金进行专户存储管理，公司、东方证券股份有限公司 （以下简称"独立财务顾问""东方证券"）、存放募集资金的银行已签订募集资金三方 监管协议，对募集资金的存放和使用情况进行监管。 罗博特科智能科技股份有限公司董事会 关于 2025 年半年度募集资金存放、管理与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于同意罗博特科智能科技股份有限公司发行股份购买 资产并募集配套资金注册的批复》（证监许可〔2025〕949 号）同意，公司向特定对象发行 人民币普通股 3,072,245 股，发行价格为人民币 124.99 元/股，募集资金总额为人民币 净额为人民币 358,438,295.01 元。募集资金已于 2025 年 5 月 26 日划至公司指定账户，天健 会计师事务所（特殊普通合伙）已对上述募集资金的资金到位情况进行了审验，并于 2025 年 5 月 27 日出 ...

Core Points - The company has issued a special report on the use of raised funds as of June 30, 2025, ensuring the information is true, accurate, and complete [1] - The company raised a total of RMB 276 million through the issuance of convertible bonds in March 2022 and RMB 301.99 million through a private placement of A-shares in September 2023 [2][5] - The company has established a fund management system to ensure the effective use of raised funds and protect investor rights [2][3] Fundraising Overview - The total amount raised from the convertible bonds was RMB 276 million, with a net amount of RMB 272 million after deducting issuance costs [1] - The total amount raised from the A-share issuance was RMB 301.99 million, with a net amount of RMB 294.84 million after deducting issuance costs [2] - As of June 30, 2025, the company has used a total of RMB 421.71 million of the raised funds, with RMB 155.79 million remaining [5][6] Fund Management and Usage - The company has implemented a dedicated account management system for the raised funds, ensuring compliance with relevant laws and regulations [2][3] - As of June 30, 2025, several fundraising accounts have been closed, and the remaining funds are stored in dedicated accounts [3][4] - The company has not engaged in any temporary use of idle funds for working capital or cash management [5][6] Project Updates and Changes - The "Construction Project of Centralized Preparation Center for Medical Institutions in Shaanxi Province" has been delayed and the completion date has been extended to December 31, 2024, due to various factors [6][9] - The company has decided to terminate the project and use the remaining funds for permanent working capital, following board and supervisory approvals [6][9] - The company has also terminated the "Quality Inspection and Testing Shared Platform Upgrade Project" and redirected the remaining funds to working capital [6][9] Compliance and Disclosure - The company has ensured that all fundraising activities and fund usage have been disclosed in a timely, truthful, accurate, and complete manner [5][6] - There have been no violations in the management of raised funds during the reporting period [5][6]